Sunday, 08/01/2010
|
Adaptive Designs in Dose-Finding Oncology Drug Combination Trials
Yuehui Wu, GlaxoSmithKline; Bingming Yi, GlaxoSmithKline; Yanmei Xu, GlaxoSmithKline
2:45 PM
|
Bayesian Adaptive Designs for Dose Escalation Studies
Anna Elizabeth McGlothlin, Eli Lilly and Company
4:05 PM
|
Using Bayesian Adaptive Designs for FDA Event Safety Studies
Jason Connor, Berry Consultants, LLC; Scott Berry, Berry Consultants, LLC; Donald Arthur Berry, MD Anderson Cancer Center
4:45 PM
|
Monday, 08/02/2010
|
A General Framework of Adaptive Designs for Early-Phase Oncology Clinical Trials
Lixin Lang, Bristol-Myers Squibb; Ralph Raymond, Bristol-Myers Squibb
|
Achieving the Benefits of Both an Internal Pilot and Interim Analysis in Small Samples
John A. Kairalla, University of Florida; Keith E. Muller, University of Florida; Christopher S. Coffey, The University of Iowa
10:35 AM
|
Applications of 'Learn' Phase Adaptive Designs
Jose Carlos Pinheiro, Johnson & Johnson; Chyi-Hung Hsu, Novartis Pharmaceuticals Corporation
2:05 PM
|
Guiding Clinicans Through the EffTox Model
Meagan E. Spychala, Rho, Inc.
2:35 PM
|
|